Orthofix Medical Inc (OFIX)

$16.25

+0.2

(+1.25%)▲

Live

Performance

  • $16.02
    $16.33
    $16.25
    downward going graph

    1.42%

    Downside

    Day's Volatility :1.9%

    Upside

    0.49%

    downward going graph
  • $9.58
    $17.67
    $16.25
    downward going graph

    41.08%

    Downside

    52 Weeks Volatility :45.81%

    Upside

    8.04%

    downward going graph

Returns

PeriodOrthofix Medical IncSector (Health Care)Index (Russel 2000)
3 Months
0.12%
3.6%
0.0%
6 Months
22.71%
10.2%
0.0%
1 Year
41.91%
19.6%
0.0%
3 Years
-55.6%
16.8%
-23.0%

Highlights

Market Capitalization
606.6M
Book Value
$14.35
Earnings Per Share (EPS)
-3.19
PEG Ratio
0.33
Wall Street Target Price
21.73
Profit Margin
-15.62%
Operating Margin TTM
-10.99%
Return On Assets TTM
-2.6%
Return On Equity TTM
-20.32%
Revenue TTM
771.6M
Revenue Per Share TTM
20.58
Quarterly Revenue Growth YOY
6.2%
Gross Profit TTM
337.2M
EBITDA
26.0M
Diluted Eps TTM
-3.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.23
EPS Estimate Next Year
-0.1
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    54%Buy
    45%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Orthofix Medical Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 33.72%

Current $16.25
Target $21.73

Company Financials

FY18Y/Y Change
Revenue
453.0M
↑ 4.43%
Net Income
13.8M
↑ 121.93%
Net Profit Margin
3.05%
↑ 1.62%
FY19Y/Y Change
Revenue
460.0M
↑ 1.53%
Net Income
-28.5M
↓ 306.08%
Net Profit Margin
-6.19%
↓ 9.24%
FY20Y/Y Change
Revenue
406.6M
↓ 11.61%
Net Income
2.5M
↓ 108.84%
Net Profit Margin
0.62%
↑ 6.81%
FY21Y/Y Change
Revenue
464.5M
↑ 14.25%
Net Income
-38.4M
↓ 1624.79%
Net Profit Margin
-8.26%
↓ 8.88%
FY22Y/Y Change
Revenue
460.7M
↓ 0.81%
Net Income
-19.7M
↓ 48.54%
Net Profit Margin
-4.29%
↑ 3.97%
FY23Y/Y Change
Revenue
746.6M
↑ 62.06%
Net Income
-151.4M
↑ 666.6%
Net Profit Margin
-20.28%
↓ 15.99%
Q1 FY23Q/Q Change
Revenue
175.2M
↑ 43.34%
Net Income
-60.9M
↑ 762.9%
Net Profit Margin
-34.78%
↓ 29.0%
Q2 FY23Q/Q Change
Revenue
187.0M
↑ 6.74%
Net Income
-39.4M
↓ 35.3%
Net Profit Margin
-21.08%
↑ 13.7%
Q3 FY23Q/Q Change
Revenue
184.0M
↓ 1.61%
Net Income
-28.9M
↓ 26.81%
Net Profit Margin
-15.68%
↑ 5.4%
Q4 FY23Q/Q Change
Revenue
200.4M
↑ 8.92%
Net Income
-22.2M
↓ 23.16%
Net Profit Margin
-11.06%
↑ 4.62%
Q1 FY24Q/Q Change
Revenue
188.6M
↓ 5.89%
Net Income
-36.0M
↑ 62.44%
Net Profit Margin
-19.1%
↓ 8.04%
Q2 FY24Q/Q Change
Revenue
198.6M
↑ 5.31%
Net Income
-33.4M
↓ 7.15%
Net Profit Margin
-16.84%
↑ 2.26%
FY18Y/Y Change
Total Assets
466.6M
↑ 15.12%
Total Liabilities
131.2M
↑ 20.69%
FY19Y/Y Change
Total Assets
495.6M
↑ 6.21%
Total Liabilities
168.0M
↑ 28.0%
FY20Y/Y Change
Total Assets
525.9M
↑ 6.1%
Total Liabilities
169.0M
↑ 0.6%
FY21Y/Y Change
Total Assets
476.6M
↓ 9.36%
Total Liabilities
139.7M
↓ 17.34%
FY22Y/Y Change
Total Assets
458.6M
↓ 3.78%
Total Liabilities
121.8M
↓ 12.83%
FY23Y/Y Change
Total Assets
925.3M
↑ 101.76%
Total Liabilities
326.6M
↑ 168.2%
Q1 FY23Q/Q Change
Total Assets
917.1M
↑ 99.97%
Total Liabilities
253.0M
↑ 107.75%
Q2 FY23Q/Q Change
Total Assets
901.3M
↓ 1.73%
Total Liabilities
261.3M
↑ 3.29%
Q3 FY23Q/Q Change
Total Assets
905.7M
↑ 0.48%
Total Liabilities
290.2M
↑ 11.05%
Q4 FY23Q/Q Change
Total Assets
925.3M
↑ 2.17%
Total Liabilities
326.6M
↑ 12.55%
Q1 FY24Q/Q Change
Total Assets
906.1M
↓ 2.08%
Total Liabilities
335.7M
↑ 2.8%
Q2 FY24Q/Q Change
Total Assets
882.0M
↓ 2.65%
Total Liabilities
336.0M
↑ 0.08%
FY18Y/Y Change
Operating Cash Flow
49.9M
↓ 6.42%
Investing Cash Flow
-61.0M
↑ 270.27%
Financing Cash Flow
3.0M
↓ 15.4%
FY19Y/Y Change
Operating Cash Flow
32.0M
↓ 35.83%
Investing Cash Flow
-22.9M
↓ 62.42%
Financing Cash Flow
-10.7M
↓ 457.1%
FY20Y/Y Change
Operating Cash Flow
74.3M
↑ 131.86%
Investing Cash Flow
-52.3M
↑ 128.29%
Financing Cash Flow
3.2M
↓ 130.36%
FY21Y/Y Change
Operating Cash Flow
18.5M
↓ 75.13%
Investing Cash Flow
-23.0M
↓ 56.03%
Financing Cash Flow
-3.6M
↓ 211.59%
FY22Y/Y Change
Operating Cash Flow
-11.5M
↓ 162.45%
Investing Cash Flow
-24.5M
↑ 6.61%
Financing Cash Flow
-78.0K
↓ 97.85%
Q1 FY23Q/Q Change
Operating Cash Flow
-34.0M
↓ 1548.89%
Investing Cash Flow
17.1M
↓ 389.56%
Financing Cash Flow
16.0M
↑ 966.96%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.5M
↓ 83.79%
Investing Cash Flow
-12.8M
↓ 175.04%
Financing Cash Flow
5.8M
↓ 63.66%

Technicals Summary

Sell

Neutral

Buy

Orthofix Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Orthofix Medical Inc
Orthofix Medical Inc
0.88%
22.71%
41.91%
-55.6%
-69.65%
Stryker Corporation
Stryker Corporation
0.83%
12.78%
40.21%
33.69%
71.83%
Boston Scientific Corp.
Boston Scientific Corp.
4.85%
29.48%
75.68%
96.28%
127.87%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
4.32%
-19.19%
1.77%
-39.29%
-7.22%
Abbott Laboratories
Abbott Laboratories
3.99%
11.51%
24.65%
-4.53%
46.22%
Medtronic Plc
Medtronic Plc
2.65%
14.48%
27.42%
-24.18%
-13.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Orthofix Medical Inc
Orthofix Medical Inc
NA
NA
0.33
-0.23
-0.2
-0.03
NA
14.35
Stryker Corporation
Stryker Corporation
40.15
40.15
2.64
12.01
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
70.26
70.26
2.14
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.67
27.67
3.65
2.6
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.83
35.83
4.31
4.67
0.14
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
30.23
30.23
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Orthofix Medical Inc
Orthofix Medical Inc
Buy
$606.6M
-69.65%
NA
-15.62%
Stryker Corporation
Stryker Corporation
Buy
$137.1B
71.83%
40.15
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$127.3B
127.87%
70.26
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$42.3B
-7.22%
27.67
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$205.1B
46.22%
35.83
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.2B
-13.49%
30.23
12.06%

Insights on Orthofix Medical Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 188.60M → 198.62M (in $), with an average increase of 5.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -36.02M → -33.44M (in $), with an average increase of 7.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 30.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 151.9%

Institutional Holdings

  • Armistice Capital, LLC

    9.82%

  • Rubric Capital Management LP

    9.68%

  • Engine Capital Management LP

    8.82%

  • BlackRock Inc

    8.35%

  • Paradigm Capital Management, Inc.

    6.70%

  • Vanguard Group Inc

    5.45%

Company Information

orthofix international began in a small farmhouse in verona italy in 1980 when orthopedic researcher giovanni de bastiani recognized the bone’s natural repair capability, a concept he called “dynamization” and with that in mind, he created the first external fixation device. today, orthofix has grown to more than 900 employees with locations in the u.s., italy, germany, france, the uk, brazil, australia and puerto rico. our products help patients in 70 countries around the world. the company is comprised of four strategic business units; biostim, biologics, extremity fixation and spine fixation. our products are widely distributed via the company's sales representatives, distributors and subsidiaries. at orthofix we are committed to clinical research and driven by new product introductions. we are proud of our strong partnerships with organizations such as the texas scottish rite hospital for children in dallas and the musculoskeletal transplant foundation. we take pride in developing

Organization
Orthofix Medical Inc
Employees
1634
CEO
Mr. Geoffrey C. Gillespie
Industry
Health Technology

Discover More

FAQs